TD Cowen analyst Joseph Thome raised the firm’s price target on PTC Therapeutics (PTCT) to $56 from $52 and keeps a Hold rating on the shares. The firm noted Sephience crossed the regulatory finish line and has launched in the U.S./EU. The launch trajectory will be closely watched and be the main stock driver in the near/medium term as the DMD franchise draws back.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $63 from $60 at RBC Capital
- PTC Therapeutics price target raised to $79 from $78 at Wells Fargo
- PTC Therapeutics Reports Q2 2025 Financial Results
- PTC Therapeutics: Balancing Optimism and Uncertainty Amidst New Product Launches and Regulatory Decisions
- PTC Therapeutics Enters Rights Satisfaction Agreement